Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer.
de Heer EC, Zois CE, Bridges E, van der Vegt B, Sheldon H, Veldman WA, Zwager MC, van der Sluis T, Haider S, Morita T, Baba O, Schröder CP, de Jong S, Harris AL, Jalving M. de Heer EC, et al. Among authors: schroder cp. J Exp Clin Cancer Res. 2023 Jun 6;42(1):143. doi: 10.1186/s13046-023-02715-z. J Exp Clin Cancer Res. 2023. PMID: 37280675 Free PMC article.
Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model.
van der Bilt AR, Terwisscha van Scheltinga AG, Timmer-Bosscha H, Schröder CP, Pot L, Kosterink JG, van der Zee AG, Lub-de Hooge MN, de Jong S, de Vries EG, Reyners AK. van der Bilt AR, et al. Among authors: schroder cp. Clin Cancer Res. 2012 Nov 15;18(22):6306-14. doi: 10.1158/1078-0432.CCR-12-0406. Epub 2012 Sep 26. Clin Cancer Res. 2012. PMID: 23014526
Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer.
Terwisscha van Scheltinga AG, Berghuis P, Nienhuis HH, Timmer-Bosscha H, Pot L, Gaykema SB, Lub-de Hooge MN, Kosterink JG, de Vries EG, Schröder CP. Terwisscha van Scheltinga AG, et al. Among authors: schroder cp. Eur J Cancer. 2014 Sep;50(14):2508-16. doi: 10.1016/j.ejca.2014.06.008. Epub 2014 Jul 12. Eur J Cancer. 2014. PMID: 25027745
Targeting breast cancer through its microenvironment: current status of preclinical and clinical research in finding relevant targets.
Nienhuis HH, Gaykema SB, Timmer-Bosscha H, Jalving M, Brouwers AH, Lub-de Hooge MN, van der Vegt B, Overmoyer B, de Vries EG, Schröder CP. Nienhuis HH, et al. Among authors: schroder cp. Pharmacol Ther. 2015 Mar;147:63-79. doi: 10.1016/j.pharmthera.2014.11.004. Epub 2014 Nov 6. Pharmacol Ther. 2015. PMID: 25444756 Review.
Immunotherapeutic options on the horizon in breast cancer treatment.
van Rooijen JM, Stutvoet TS, Schröder CP, de Vries EG. van Rooijen JM, et al. Among authors: schroder cp. Pharmacol Ther. 2015 Dec;156:90-101. doi: 10.1016/j.pharmthera.2015.09.003. Epub 2015 Sep 24. Pharmacol Ther. 2015. PMID: 26388292 Review.
Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer.
Koch M, de Jong JS, Glatz J, Symvoulidis P, Lamberts LE, Adams AL, Kranendonk ME, Terwisscha van Scheltinga AG, Aichler M, Jansen L, de Vries J, Lub-de Hooge MN, Schröder CP, Jorritsma-Smit A, Linssen MD, de Boer E, van der Vegt B, Nagengast WB, Elias SG, Oliveira S, Witkamp AJ, Mali WP, Van der Wall E, Garcia-Allende PB, van Diest PJ, de Vries EG, Walch A, van Dam GM, Ntziachristos V. Koch M, et al. Among authors: schroder cp. Cancer Res. 2017 Feb 1;77(3):623-631. doi: 10.1158/0008-5472.CAN-16-1773. Epub 2016 Nov 22. Cancer Res. 2017. PMID: 27879266
Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study.
Lamberts LE, Koch M, de Jong JS, Adams ALL, Glatz J, Kranendonk MEG, Terwisscha van Scheltinga AGT, Jansen L, de Vries J, Lub-de Hooge MN, Schröder CP, Jorritsma-Smit A, Linssen MD, de Boer E, van der Vegt B, Nagengast WB, Elias SG, Oliveira S, Witkamp AJ, Mali WPTM, Van der Wall E, van Diest PJ, de Vries EGE, Ntziachristos V, van Dam GM. Lamberts LE, et al. Among authors: schroder cp. Clin Cancer Res. 2017 Jun 1;23(11):2730-2741. doi: 10.1158/1078-0432.CCR-16-0437. Epub 2016 Nov 9. Clin Cancer Res. 2017. PMID: 28119364 Clinical Trial.
144 results